Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 3/2017

01-03-2017 | Review Article

Clinical Pharmacokinetics and Pharmacodynamics of Safinamide

Authors: Thomas Müller, Paul Foley

Published in: Clinical Pharmacokinetics | Issue 3/2017

Login to get access

Abstract

The symptoms of Parkinson’s disease (PD) reflect disruptions of a number of brain neurotransmitter systems of varying type and degree. Pharmacological agents with multiple neurochemical mechanisms of action are therefore promising candidates for countering these problems and providing comprehensive symptomatic relief for patients. The pharmacological profile of safinamide includes reversible monoamine oxidase B inhibition, blockage of voltage-dependent Na+ channels, modulation of Ca2+ channels, and inhibition of glutamate release. Safinamide is administered once daily at oral doses of 50–100 mg; it is well-tolerated and safe. Clinical trials have found that it ameliorates motor symptoms when added to established levodopa or single dopamine receptor agonist therapy. The future role of safinamide in PD may be that it enables a reduction in the dosage of dopamine replacement therapies, thereby reducing the adverse effects associated with these treatments. The clinical convenience (once-daily administration), safety, and tolerability of safinamide are better than those of dopamine receptor agonists. The introduction of safinamide reflects a change of approach to drug development for anti-parkinsonian agents in that its broad spectrum of action corresponds to the multiple heterogeneous alterations of brain neurochemistry in PD, rather than being targeted at a single receptor type or neurochemical process. Safinamide is a promising new instrument for the effective symptomatic therapy of PD.
Literature
1.
Riederer P, Gerlach M, Müller T, Reichmann H. Relating mode of action to clinical practice: dopaminergic agents in Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:466–79.CrossRefPubMed
2.
Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol. 1999;56:1383–6.CrossRefPubMed
3.
Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson’s disease (EASED study). Mov Disord. 2015;30:788–95.CrossRefPubMedPubMedCentral
4.
LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63:295–302.CrossRefPubMed
5.
Weiner WJ. What do clinical trials tell us about treating patients? Parkinsonism Relat Disord. 2009;15:S34–7.CrossRefPubMed
6.
Bartl J, Müller T, Grünblatt E, Gerlach M, Riederer P. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. J Neural Transm. 2014;121:379–83.CrossRefPubMed
7.
8.
Akao Y, Maruyama W, Shimizu S, Yi H, Nakagawa Y, Shamoto-Nagai M, et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem. 2002;82:913–23.CrossRefPubMed
9.
Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M. An anti-Parkinson’s disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2002;326:105–8.CrossRefPubMed
10.
Bar-Am O, Weinreb O, Amit T, Youdim MB. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 2005;19:1899–901.PubMed
11.
12.
Binda C, Wang J, Pisani L, Caccia C, Carotti A, Salvati P, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem. 2007;50:5848–52.CrossRefPubMed
13.
Riederer P, Lachenmayer L, Laux G. Clinical applications of MAO-inhibitors. Curr Med Chem. 2004;11:2033–43.CrossRefPubMed
14.
Müller T, Przuntek H, Rieks M, Mackowiak A. Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells. Neurol Res. 2008;30:417–9.CrossRefPubMed
15.
Di Stefano AF, Rusca A. Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers. Naunyn Schmiedebergs Arch Pharmacol. 2011;384:505–15.CrossRefPubMed
16.
Marquet A, Kupas K, Johne A, Astruc B, Patat A, Krosser S, et al. The effect of safinamide, a novel drug for Parkinson’s disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. Clin Pharmacol Ther. 2012;92:450–7.PubMed
17.
Gregoire L, Jourdain VA, Townsend M, Roach A, Di PT. Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord. 2013;19:508–14.CrossRefPubMed
18.
Podurgiel S, Collins-Praino LE, Yohn S, Randall PA, Roach A, Lobianco C, et al. Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor. Pharmacol Biochem Behav. 2013;105:105–11.CrossRefPubMed
19.
Marzo A, Dal Bo L, Monti NC, Crivelli F, Ismaili S, Caccia C, et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res. 2004;50:77–85.CrossRefPubMed
20.
Maj R, Fariello RG, Ukmar G, Varasi M, Pevarello P, McArthur RA, et al. PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat. Eur J Pharmacol. 1998;359:27–32.CrossRefPubMed
21.
Sadeghian M, Mullali G, Pocock JM, Piers T, Roach A, Smith KJ. Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson’s disease. Neuropathol Appl Neurobiol. 2016;42(5):423–35.CrossRefPubMed
22.
23.
Krosser S, Marquet A, Gallemann D, Wolna P, Fauchoux N, Hermann R, et al. Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects. Biopharm Drug Dispos. 2012;33:550–9.CrossRefPubMed
24.
Leuratti C, Sardina M, Ventura P, Assandri A, Muller M, Brunner M. Disposition and metabolism of safinamide, a novel drug for Parkinson’s disease, in healthy male volunteers. Pharmacology. 2013;92:207–16.CrossRefPubMed
25.
Seithel-Keuth A, Johne A, Freisleben A, Kupas K, Lissy M, Krosser S. Absolute Bioavailability and effect of food on the disposition of safinamide immediate release tablets in healthy adult subjects. Clin Pharmacol Drug Dev. 2013;2:79–89.CrossRefPubMed
26.
Fariello RG, McArthur RA, Bonsignori A, Cervini MA, Maj R, Marrari P, et al. Preclinical evaluation of PNU-151774E as a novel anticonvulsant. J Pharmacol Exp Ther. 1998;285:397–403.PubMed
27.
Stocchi F, Arnold G, Onofrj M, Kwiecinski H, Szczudlik A, Thomas A, Safinamide Parkinson’s Study Group, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology. 2004;63:746–8.CrossRefPubMed
28.
Stocchi F, Borgohain R, Onofrj M, Schapira AH, Bhatt M, Lucini V, Study 015 Investigators, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson’s disease patients. Mov Disord. 2012;27:106–12.CrossRefPubMed
29.
Schapira AH, Stocchi F, Borgohain R, Onofrj M, Bhatt M, Lorenzana P, et al. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s disease. Eur J Neurol. 2013;20:271–80.CrossRefPubMed
30.
Barone P, Fernandez HH, Ferreira J, Muller T, Saint-Hilaire M, Stacy M, et al. Safinamide as an add-on therapy to a stable dose of a single dopamine agonist: results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic Parkinson disease (PD) patients (MOTION study) [abstract]. Neurology. 2013;80(7 Suppl):P01.061.
31.
Hauser RA, Silver D, Choudhry A, Eyal E, Isaacson S. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson’s disease. Mov Disord. 2014;29:1028–34.CrossRefPubMed
32.
Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord. 2014;29:229–37.CrossRefPubMed
33.
Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord. 2014;29:1273–80.CrossRefPubMed
34.
Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost W, Kulisevsky J, et al. Safinamide add on to l-dopa: a randomized, placebo-controlled, 24-week global trial in patients with Parkinson’s disease (PD) and motor fluctuations (SETTLE) [abstract]. Neurology. 2013;80(7 Suppl):P01.062.
35.
Przuntek H, Conrad B, Dichgans J, Kraus PH, Krauseneck P, Pergande G, et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol. 1999;6:141–50.CrossRefPubMed
36.
Schnitker J, Müller T. Meta-analysis of placebo-controlled clinical trials of safinamide and entacapone as add-on therapy to levodopa in the treatment of Parkinson’s disease. Eur Neurol Rev. 2015;10:15–22.CrossRef
37.
Ambrozi L, Danielczyk W. Treatment of impaired cerebral function in psychogeriatric patients with memantine–results of a phase II double-blind study. Pharmacopsychiatry. 1988;21:144–6.CrossRefPubMed
38.
Comi G, Leocani L. Assessment, pathophysiology and treatment of fatigue in multiple sclerosis. Expert Rev Neurother. 2002;2:867–76.CrossRefPubMed
39.
Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24:1641–9.CrossRefPubMed
40.
Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology. 2007;32:1011–20.CrossRefPubMed
41.
Fava M, Rosenbaum JF, Kolsky AR, Alpert JE, Nierenberg AA, Spillmann M, et al. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol. 1999;19:329–35.CrossRefPubMed
42.
Moreau JL, Borgulya J, Jenck F, Martin JR. Tolcapone: a potential new antidepressant detected in a novel animal model of depression. Behav Pharmacol. 1994;5:344–50.CrossRefPubMed
43.
Gasparini M, Fabrizio E, Bonifati V, Meco G. Cognitive improvement during tolcapone treatment in Parkinson’s disease. J Neural Transm. 1997;104:887–94.CrossRefPubMed
44.
Kayser AS, Allen DC, Navarro-Cebrian A, Mitchell JM, Fields HL. Dopamine, corticostriatal connectivity, and intertemporal choice. J Neurosci. 2012;32:9402–9.CrossRefPubMed
45.
Roussos P, Giakoumaki SG, Bitsios P. Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism. Biol Psychiatry. 2009;66:997–1004.CrossRefPubMed
46.
Dimpfel W, Hoffmann JA. Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro. BMC Pharmacol. 2011;11:2.CrossRefPubMedPubMedCentral
47.
Fabbri M, Rosa MM, Abreu D, Ferreira JJ. Clinical pharmacology review of safinamide for the treatment of Parkinson’s disease. Neurodegener Dis Manag. 2015;5:481–96.CrossRefPubMed
48.
Kornhuber J, Bormann J, Retz W, Hubers M, Riederer P. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol. 1989;166:589–90.CrossRefPubMed
49.
Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson’s disease: a double-blind crossover randomized study. Clin Neuropharmacol. 1999;22:273–6.PubMed
50.
Varanese S, Howard J, Di RA. NMDA antagonist memantine improves levodopa-induced dyskinesias and “on-off” phenomena in Parkinson’s disease. Mov Disord. 2010;25:508–10.CrossRefPubMed
51.
Müller T, Russ H. Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease. Expert Opin Pharmacother. 2006;7:1715–30.CrossRefPubMed
52.
Hoy SM, Keating GM. Rasagiline: a review of its use in the treatment of idiopathic Parkinson’s disease. Drugs. 2012;72:643–69.CrossRefPubMed
53.
LeWitt PA. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition. Clin Neuropharmacol. 2007;30:305–7.CrossRefPubMed
54.
Griffin E, Brown JN. Pregabalin for the treatment of restless legs syndrome. Ann Pharmacother. 2016;50:586–91.CrossRefPubMed
55.
Barone P, Cattaneo C, La Ferla R, Bonnizoni E, Sardina M. Significant reduction of pain treatments with safinamide administered as add-on therapy to levodopa in patients with Parkinson’s disease and fluctuation [abstract]. Mov Disord. 2015;22(Suppl 1):293.
56.
Errington AC, Stohr T, Lees G. Voltage gated ion channels: targets for anticonvulsant drugs. Curr Top Med Chem. 2005;5:15–30.CrossRefPubMed
Metadata
Title
Clinical Pharmacokinetics and Pharmacodynamics of Safinamide
Authors
Thomas Müller
Paul Foley
Publication date
01-03-2017
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 3/2017
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-016-0449-5

Other articles of this Issue 3/2017

Clinical Pharmacokinetics 3/2017 Go to the issue

Original Research Article

A Strategy for Dosing Vancomycin to Therapeutic Targets Using Only Trough Concentrations

Current Opinion

Towards a Model-Based Dose Recommendation for Doxorubicin in Children

Original Research Article

Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients

Original Research Article

Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?

Short Communication

Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure

Review Article

Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union